Key result
Pitavastatin reduces HbA1c by ~0.2 percentage points compared with atorvastatin in type 2 diabetes.
Why the study?
The distinct effects of different statins on glycemic control in type 2 diabetic patients with hypercholesterolemia have not been fully evaluated.
Does pitavastatin improve glycemic control compared to atorvastatin in type 2 diabetic patients with hypercholesterolemia?
RCT (n=28)
Open-label
quasi-randomized
Does pitavastatin improve glycemic control compared to atorvastatin in type 2 diabetic patients with hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
Pitavastatin exerts a more favorable effect on glycemic control than atorvastatin in Japanese patients with type 2 diabetes and hypercholesterolemia.
AbstractAims/IntroductionThe distinct effects of different statins on glycemic control have not been fully evaluated. In this open‐label, prospective, cross‐over clinical trial, we compared the effects of pitavastatin and atorvastatin on glycemic control in type 2 diabetic patients with hypercholesterolemia.Materials and MethodsA total of 28 Japanese type 2 diabetics with hypercholesterolemia treated with rosuvastatin (2.5 mg/day) for at least 8 weeks were recruited to this quasi‐randomized cross‐over study. At study entry, the patients assigned to sequence 1 received pitavastatin (2 mg/day) for 12 weeks in period 1 and atorvastatin (10 mg/day) for another 12 weeks in period 2, whereas patients assigned to sequence 2 received atorvastatin (10 mg/day) for 12 weeks in period 1 and pitavastatin (2 mg/day) for another 12 weeks in period 2. Blood samples were collected at three visits (baseline, after 12 and 24 weeks).ResultsLipid control was similar in both statins. The difference in glycated hemoglobin between pitavastatin and atorvastatin treatments was −0.18 (95% confidence interval −0.34 to −0.02; P = 0.03). Compared with atorvastatin, pitavastatin treatment significantly lowered the levels of glycoalbumin, fasting glucose and homeostasis model assessment of insulin resistance.ConclusionsOur results showed that treatment with pitavastatin had a more favorable outcome on glycemic control in patients with type 2 diabetes compared with atorvastatin. This trial was registered with UMIN (no. 000003554).
No takes yet. Share an insight, caveat, or question.
Mita et al. (2013) conducted an RCT in Type 2 diabetes with hypercholesterolemia (n=28). Pitavastatin vs. Atorvastatin (10 mg/day) was evaluated on Difference in glycated hemoglobin (MD -0.18, 95% CI -0.34 to -0.02, p=0.03). Pitavastatin reduced glycated hemoglobin compared with atorvastatin in patients with type 2 diabetes and hypercholesterolemia.
Synapse has enriched 10 related papers. Consider them for comparative context: